JNJ - Johnson & Johnson

NYSE - Nasdaq Real Time Price. Currency in USD
132.28
-0.22 (-0.17%)
As of 11:58AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close132.50
Open132.49
Bid131.98 x 1100
Ask131.97 x 800
Day's Range131.41 - 133.58
52 Week Range121.00 - 148.99
Volume3,465,122
Avg. Volume7,123,291
Market Cap351.2B
Beta (3Y Monthly)0.76
PE Ratio (TTM)21.97
EPS (TTM)6.02
Earnings DateOct 15, 2019
Forward Dividend & Yield3.80 (2.82%)
Ex-Dividend Date2019-08-26
1y Target Est149.17
Trade prices are not sourced from all markets
  • Johnson & Johnson CFO on the opioid crisis: 'We don’t believe we were the cause'
    Yahoo Finance20 hours ago

    Johnson & Johnson CFO on the opioid crisis: 'We don’t believe we were the cause'

    Pharmaceutical companies are facing increasing scrutiny for their alleged roles in the opioid crisis. Its next target? Johnson & Johnson (JNJ).

  • Healthcare ETFs in Focus on JNJ's Q2 Earnings Beat
    Zacks1 hour ago

    Healthcare ETFs in Focus on JNJ's Q2 Earnings Beat

    Johnson & Johnson beat the second-quarter earnings and revenue estimates but warned on competition from generics and biosimilars that could impact its third-quarter results.

  • Company News for Jul 17, 2019
    Zacks2 hours ago

    Company News for Jul 17, 2019

    Companies In The News Are: JNJ,DPZ,JBHT,CP

  • Thomson Reuters StreetEvents12 hours ago

    Edited Transcript of JNJ earnings conference call or presentation 16-Jul-19 12:30pm GMT

    Q2 2019 Johnson & Johnson Earnings Call

  • Opioid makers dumped 76 billion pills onto U.S. market over 7 critical years, data shows
    MarketWatch12 hours ago

    Opioid makers dumped 76 billion pills onto U.S. market over 7 critical years, data shows

    Newly released federal data shows how drugmakers and distributors increased shipments of opioid painkillers across the U.S. as the nation’s addiction crisis accelerated from 2006 to 2012.

  • GuruFocus.com19 hours ago

    Johnson & Johnson Registers 2nd-Quarter Earnings Beat

    Shares slide on mounting legal costs Continue reading...

  • Here's Why J&J Stock Is Sliding Despite A Second-Quarter Beat
    Investor's Business Daily19 hours ago

    Here's Why J&J Stock Is Sliding Despite A Second-Quarter Beat

    JNJ stock slipped Tuesday after Dow Jones component Johnson & Johnson topped Wall Street's second-quarter earnings and revenue forecasts, but kept its full-year profit guidance intact.

  • US STOCKS-Wall Street slips as bank earnings, Trump trade comments weigh
    Reuters19 hours ago

    US STOCKS-Wall Street slips as bank earnings, Trump trade comments weigh

    U.S. stocks edged lower on Tuesday as quarterly results from banks added to concerns about lower interest rates dampening their profits, while comments from U.S. President Donald Trump on trade also dragged down Wall Street's major indexes. Johnson & Johnson shares slipped 1.6% after the diversified healthcare company warned that competition from generic and copycat drugs could impact its third-quarter results.

  • Dow Jones Today: Earnings Disappointments
    InvestorPlace20 hours ago

    Dow Jones Today: Earnings Disappointments

    With some marquee earnings reports out today, it would have been reasonable to expect some more action out of the major U.S. equity benchmarks. By the time the closing bell sounded, though, Tuesday had all the appearances of just another boring summertime trading day.Source: Shutterstock The Nasdaq Composite fell 0.43% while the S&P 500 gave up 0.34%. The Dow Jones Industrial Average was mostly flat, settling down 0.09%.Arguably adding to the disappointment that was Tuesday's broader market action was that there was some encouraging economic data out earlier in the day. Retail sales rose for a fourth consecutive month in June, indicating that one of the primary drivers of the U.S. economy, the consumer, remains sturdy. And that data point does not even include Amazon's (NASDAQ:AMZN) Prime Day, which shattered records.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 9 Retail Stocks Goldman Sachs Says Are Ready to Rip Prime Day spanned into today and some analysts forecast $5 billion or more in sales for Amazon, easily topping 2018's Prime Day haul of $3.2 billion. Bottom line: the consumer is in good health and that should be meaningful for riskier assets going forward.Now let's get into some of those earnings reports. Boffo BanksDow component JPMorgan Chase (NYSE:JPM), the largest U.S. bank, was one of the blue-chip index's standouts Tuesday, gaining 1.06%, after the company said it earned $2.59 a share on revenue of $29.57 billion. Analysts were expecting earnings of $2.51 per share and revenue of $28.9 billion.As was noted here yesterday, net interest margins could become problematic for banks if interest rates decline. To that end, JPMorgan pared its 2019 net interest margin guidance to $57.5 billion from $58 billion.Goldman Sachs (NYSE:GS) was another Dow leader today, adding 1.87% after the investment bank said it earned $5.81 a share on revenue of $9.46 billion. Analysts expected earnings of $4.89 per share on revenue of $8.83 billion."Institutional client revenue, which includes trading, slipped 3%, while investment banking revenue was down 9%. However, revenue from the bank's investing and lending business rose 16%, its highest quarterly performance in eight years," according to Reuters. A Beat, but DisappointmentPharmaceuticals giant Johnson & Johnson (NYSE:JNJ) slipped 1.64% despite delivering an upbeat second-quarter report. The healthcare company said it earned $2.58 per share on sales of $20.56 billion. Wall Street expected a profit of $2.46 per share on sales of $20.29 billion.More importantly, JNJ boosted its 2019 sales forecast, excluding currency movement, to $82.4 billion to $83.2 billion, from an original range of $82 billion to $82.8 billion and the stock still declined. Credit Suisse resumed coverage of JNJ today with a $156 price target, implying significant upside from current levels. Quick AsideOnce again, Dow Inc (NYSE:DOW) was one of the Dow's best performers today, surging 2.73%. The stock has been on a torrid pace as of late. Investors considering the chemical maker may want to go here to mull over some of the bullish catalysts for the name. Bottom LineToday's earnings reports were mostly solid. It's certainly hard to quibble with JNJ raising revenue guidance, but plenty of tests remain this week and trade is clearly still an issue. President Donald Trump confirmed as much, noting the U.S. and China still have a long way to go on trade.Thursday is potentially significant day on the earnings front with Microsoft (NASDAQ:MSFT) and UnitedHealth (NYSE:UNH) among the Dow components reporting. Investors looking for a particular factor to watch should consider profit margins, regardless of company or sector."Many investors and analysts say a potential decline in profit margins--a measurement of how much a company's sales exceed its costs--is more worrisome than contracting earnings in the second quarter," according to the Wall Street Journal.Todd Shriber does not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Retail Stocks Goldman Sachs Says Are Ready to Rip * 7 Services Stocks to Buy for the Rest of 2019 * 6 Stocks to Buy and 1 to Sell Based on Insider Trading The post Dow Jones Today: Earnings Disappointments appeared first on InvestorPlace.

  • Johnson & Johnson (JNJ) Q2 2019 Earnings Call Transcript
    Motley Fool21 hours ago

    Johnson & Johnson (JNJ) Q2 2019 Earnings Call Transcript

    JNJ earnings call for the period ending June 30, 2019.

  • J&J Ups Sales Forecast as Cancer Drugs Drive Growth
    Bloomberg21 hours ago

    J&J Ups Sales Forecast as Cancer Drugs Drive Growth

    (Bloomberg) -- Johnson & Johnson raised its revenue guidance for the year, as strong sales in its pharmaceutical unit helped cushion a decline in the consumer and medical technology businesses.Second-quarter adjusted earnings were $2.58 a share, topping the $2.45 average of analysts’ estimates. To read more details on the results, click here.Key InsightsThe company’s full revenue is actually down from a year prior. Part of that can be attributed to the company’s divestiture of its medical sterilization business, ASP, which it sold to Fortive Corp. earlier this year. The company was also hit badly by foreign exchange rates. Almost half of J&J’s sales come from outside the U.S., and its fastest-growing segment -- overseas pharmaceuticals -- had its growth cut nearly in half because of currency fluctuations.J&J’s drug business is the largest of the company’s three main segments and accounts for more than half of all revenue. Its cancer drugs, including Darzalex and Imbruvica, drove growth in the quarter and were up 9.8% from a year prior.Market ReactionThe shares were down 1% to $133.41 at 9:43 a.m. in New York. The stock is up 4.4% this year to date as of Monday’s close, trailing the broader market.(Corrects spelling of cancer drug Darzalex in “Key Insights” section.)To contact the reporter on this story: Riley Griffin in New York at rgriffin42@bloomberg.netTo contact the editor responsible for this story: Drew Armstrong at darmstrong17@bloomberg.netFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • J&J stock falls despite earnings beat and guidance boost
    MarketWatch22 hours ago

    J&J stock falls despite earnings beat and guidance boost

    Shares of Johnson & Johnson fell Tuesday afternoon, despite the company reporting second-quarter earnings and revenue that soundly beat Wall Street expectations.

  • Johnson & Johnson Is A Massive Pharma Stock — But Should You Buy It?
    Investor's Business Daily22 hours ago

    Johnson & Johnson Is A Massive Pharma Stock — But Should You Buy It?

    JNJ stock tried to break out in June. But several lawsuits claiming Johnson & Johnson baby powder caused cancer are weighing on shares. So, is the Dow Jones component a buy right now?

  • GuruFocus.com22 hours ago

    US Stocks Little Moved as Earnings Roll In Tuesday

    Domino's Pizza falls on weak revenue Continue reading...

  • Johnson & Johnson Earnings: JNJ Stock Dips Despite Q2 Beat, Raised Guidance
    InvestorPlace23 hours ago

    Johnson & Johnson Earnings: JNJ Stock Dips Despite Q2 Beat, Raised Guidance

    Johnson & Johnson earnings for the second quarter of 2019 have JNJ stock down on Tuesday.Source: Shutterstock Johnson & Johnson (NYSE:JNJ) reported earnings per share of $2.58 for the second quarter of the year. This is an increase over the company's earnings per share of $2.10 from the same time last year. It also beat out Wall Street's earnings per share estimate of $2.46 for the quarter, but couldn't keep JNJ stock from falling today.Net income reported in the Johnson & Johnson earnings report for the second quarter of 2019 comes in at $5.61 billion. This is up roughly 42% from the company's net income of $3.95 billion reported in the second quarter of the previous year.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe Johnson & Johnson earnings report for the second quarter of the year has revenue coming in at $20.56 billion. This is a drop from the company's revenue of $20.83 billion reported in the same period of the year prior. Despite this, it still comes in above analysts' revenue estimate of $20.29 billion for the quarter, but JNJ stock is still falling on Tuesday.Johnson & Johnson also takes time in its most recent earnings report to update its 2019 guidance. This includes expecting its operational sales to increase between 3.2% and 3.7% from last year. However, the company doesn't increase its earnings per share estimate for the year even after beating estimates this quarter. * 9 Retail Stocks Goldman Sachs Says Are Ready to Rip So what exactly is dragging JNJ stock down today? Concerns from the company about its large amount of lawsuits is one issue. Pressure from the government about its alleged role in the opioid crisis also isn't doing it any favors, either.JNJ stock was down 1% as of Tuesday afternoon. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Retail Stocks Goldman Sachs Says Are Ready to Rip * 7 Services Stocks to Buy for the Rest of 2019 * 6 Stocks to Buy and 1 to Sell Based on Insider Trading As of this writing, William White did not hold a position in any of the aforementioned securities.The post Johnson & Johnson Earnings: JNJ Stock Dips Despite Q2 Beat, Raised Guidance appeared first on InvestorPlace.

  • GuruFocus.com23 hours ago

    Johnson & Johnson Jumps on Earnings Beat

    Sales, however, are going down Continue reading...

  • AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio
    Zacksyesterday

    AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio

    AbbVie (ABBV) buys Mavupharma to develop novel treatments for cancer using the latter's STING signaling pathway.

  • Better-Than Expected Retail Sales in June
    Zacksyesterday

    Better-Than Expected Retail Sales in June

    Better-Than Expected Retail Sales in June

  • Zacksyesterday

    J&J (JNJ) Beats on Q2 Earnings, Ups 2019 Sales Growth View

    J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2019 and raises 2019 guidance for operational sales growth for the second time this year.

  • Dow Jones Leads Stock Market Action, As Three Blue Chip Stocks Report Earnings
    Investor's Business Dailyyesterday

    Dow Jones Leads Stock Market Action, As Three Blue Chip Stocks Report Earnings

    The Dow Jones industrials led the flattish stock market action early Tuesday. Goldman Sachs moved further above a buy point after its earnings release.

  • Retail Sales Up, Import Prices Down, Q2 Earnings Solid
    Zacksyesterday

    Retail Sales Up, Import Prices Down, Q2 Earnings Solid

    Retail Sales outperformed, Imports & Exports were lower, and JPM, WFC, GS and JNJ outperformed earnings expectations.

  • Benzingayesterday

    Mostly Strong Results For Big Banks, And J&J Another Solid Earnings Performer

    Big banks continue to grow their profits, but the initial market reaction to earnings from JPMorgan Chase & Co (NYSE: JPM) and Goldman Sachs Group Inc (NYSE: GS) looks mixed early Tuesday. Both of the banks easily beat earnings per share estimates, but that included tax credits and other one-time items. At JPM, it looks like consumer banking was a strong suit, but investment banking and equity trading results came up short of analysts’ estimates.